Apelian David 4
4 · Eiger BioPharmaceuticals, Inc. · Filed Aug 18, 2022
Insider Transaction Report
Form 4
Apelian David
Director
Transactions
- Sale
Common Stock
2022-08-16$9.81/sh−5,000$49,031→ 11,000 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 13, 2022.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.80 to $ $9.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.